NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), F45 Training Holdings, Inc (NYSE: FXLV), PROG Holdings, Inc. (NYSE: PRG) and UiPath, Inc. (NYSE: PATH). Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

on 09/22/2022, Reuters reported that advisers to the US Food and Drug Administration “voted against recommending Spectrum Pharmaceuticals’ investigational drug to treat patients with a form of non-small cell lung cancer. The FDA panel voted 9-4 against the oral drug poziotinib, citing low efficacy, high levels of toxicity and lack of dose optimization. The panel’s decision was in line with information documents released by the drug agency on Tuesday, which raised concerns about the effectiveness of the treatment compared to existing drugs such as Daiichi Sankyo’s 4568.T AstraZenecas Enhertu.”

As a result of this news, Spectrum’s stock price fell $0.207 per share, or 32.65%, to close at $0.427 per share on September 23, 2022.

For more information on Spectrum testing, see: https://bespc.com/cases/SPPI

F45 Training Holdings, Inc. (NYSE:FXLV)

On or about July 15, 2021, F45 Training completed its initial public offering (“IPO”), selling 18.75 million shares at a price of $16.00 per share.

Then, on July 26, 2022, F45 issued a press release titled “F45 Training Announces Strategic Update”. In the press release, F45 Training provided an updated 2022 revenue guidance in the range of $120-130 million, well below the previous guidance of $255-275 million, citing the continued macroeconomic…